RGD‐based PET tracers for imaging receptor integrin αvβ3 expression. (16th February 2013)

• Record Type: Journal Article
• Authors: Cai, Hancheng; Conti, Peter S
• Is Part Of: Journal of labelled compounds & radiopharmaceuticals. Volume 56:Number 5(2013)
• Page Start: 264
• Page End: 279
• Publication Date: 2013-02-16
• Subjects: Tracers (Chemistry) -- Periodicals; Radiopharmaceuticals -- Periodicals; 615.8424
• DOI: 10.1002/jlcr.2999
• Languages: English
• ISSNs: 0362-4803

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Positron emission tomography (PET) imaging of receptor integrin α_vβ₃ expression may play a key role in the early detection of cancer and cardiovascular diseases, monitoring disease progression, evaluating therapeutic response, and aiding anti‐angiogenic drugs discovery and development. The last decade has seen the development of new PET tracers for in vivo imaging of integrin α_vβ₃ expression along with advances in PET chemistry. In this review, we will focus on the radiochemistry development of PET tracers based on arginine–glycine–aspartic acid (RGD) peptide, present an overview of general strategies for preparing RGD‐based PET tracers, and review the recent advances in preparations of ¹⁸F‐labeled, ⁶⁴Cu‐labeled, and ⁶⁸Ga‐labeled RGD tracers, RGD‐based PET multivalent probes, and RGD‐based PET multimodality probes for imaging receptor integrin α_vβ₃ expression.</p> </abstract>